| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/27/2007 | CA2419290C Quick-disintegrating tablet in the buccal cavity and manufacturing method thereof |
| 03/27/2007 | CA2267416C Method for producing liposomes with increased percent of compound encapsulated |
| 03/27/2007 | CA2247520C Pharmaceutical composition with base of rhein or diacerhein with improved biological availability |
| 03/27/2007 | CA2242750C Antibodies with reduced net positive charge |
| 03/27/2007 | CA2209669C Composition and methods for transdermal delivery of acid-labile drugs |
| 03/27/2007 | CA2208149C Sustained release caffeine formulation |
| 03/26/2007 | CA2560798A1 Administering pharmaceutical compositions to the mammalian central nervous system |
| 03/22/2007 | WO2007032993A2 Surfactant systems for delivery of organic compounds |
| 03/22/2007 | WO2007032727A1 Particulate lipid pharmaceutical composition |
| 03/22/2007 | WO2007032375A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE α-IONONE |
| 03/22/2007 | WO2007032340A1 COMPOSITION CONTAINING α-LIPOIC ACID |
| 03/22/2007 | WO2007032262A1 Flavor composition or fragrance composition, and flavor-improving agent |
| 03/22/2007 | WO2007032225A1 Liposome, method of producing liposome and method of controlling reaction in microreaction space |
| 03/22/2007 | WO2007031753A2 Topical film-forming monophasic formulations |
| 03/22/2007 | WO2007031741A1 Pseudomonas exotoxin a cd4+ t-cell epitopes |
| 03/22/2007 | WO2007031734A1 Comb polymers |
| 03/22/2007 | WO2007031326A2 3-(2-dimethylaminomethyl cyclohexyl) phenol retard formulation |
| 03/22/2007 | WO2007031266A2 Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine |
| 03/22/2007 | WO2006125668A3 Anti-cd16 binding molecules |
| 03/22/2007 | WO2006122905A3 A substantially water-free pressurised propellant mixture |
| 03/22/2007 | WO2006031931A3 Reducing er stress in the treatment of obesity and diabetes |
| 03/22/2007 | WO2006030217A3 Drug conjugates of long chain fatty acid or ester moieties as protein binding prodrugs |
| 03/22/2007 | WO2005092377A9 Cytotoxicity mediation of cells evidencing surface expression of cd63 |
| 03/22/2007 | US20070066813 Immunoglobulin fusion comprising blood glycoprotein with reduced glycosylation for use in prevention and treatment of septic shock, cachexia, viral and parasitic infection, autoimmune, arthritic and/or graft rejection |
| 03/22/2007 | US20070066798 Diagnostic and therapeutic use of antibodies against the urokinase receptor |
| 03/22/2007 | US20070066686 Infusion preparation containing (2r)-2-propyloctanoic acid as at the active ingredient |
| 03/22/2007 | US20070066565 Cyclic maltosylmatose |
| 03/22/2007 | US20070066563 alkaline deproteination and subsequent elimination of water-soluble components consists in that the so obtained insoluble glucan is subsequently hydrated by wet grinding; heat sterilizing, results in a fungal polysaccharide with the beta -(1,3)-D-bond in the principal chain |
| 03/22/2007 | US20070066561 Drug delivery and targeting with vitamin B12 conjugates |
| 03/22/2007 | US20070066555 Gene expression inhibition; sustained release; for reduction of neuronal cell death, inflammation, and scar formation; improves wound healing, skin rejuvenation and thickening |
| 03/22/2007 | US20070066553 Immunostimulatory nucleic acid molecules |
| 03/22/2007 | US20070066535 Novel amino acid sequences are within the carboxy termini of fibrinogen; useful for cell culture and cell separation |
| 03/22/2007 | US20070066528 Methods and compositions for treating polycystic ovary syndrome |
| 03/22/2007 | US20070065517 Modafinil Pharmaceutical Compositions |
| 03/22/2007 | US20070065509 Comprises ciprofloxacin and hydroxypropylmethylcellulose for improving visocisty |
| 03/22/2007 | US20070065495 Transdermal hormone delivery system: compositions and methods |
| 03/22/2007 | US20070065492 Cladribine formulations for improved oral and transmucosal delivery |
| 03/22/2007 | US20070065488 Food composition having anti-stress action |
| 03/22/2007 | US20070065487 Trans-lutein xantophyll ester of high purity and high bioavailability in micellar solution and a process for the preparation thereof |
| 03/22/2007 | US20070065460 differentail precipitation, concentration, difiltration of polysacchride using cationic detergent hexadecyltrimethyl ammonium bromide, ethanol, a anionic detergent sodium deoxycholate; straightforward, reproducible and cost-effective; polysaccharide is obtained from Haemophilus influenza type b |
| 03/22/2007 | US20070065454 Liposomal vaccine |
| 03/22/2007 | US20070065451 Enhancement of intracellular delivery and tissue targeting of drugs and genes |
| 03/22/2007 | US20070065440 Antibody compositions and methods |
| 03/22/2007 | US20070065432 Antibody fragment-targeted immunoliposomes for systemic gene delivery |
| 03/22/2007 | US20070065426 Tumor necrosis factor binding ligands |
| 03/22/2007 | US20070065407 Interferon-Alpha Polypeptides and Conjugates |
| 03/22/2007 | US20070065371 Novel Dry Powder Inhalation System For Transpulmonary Administration |
| 03/22/2007 | US20070065370 Suspension aerosol formulationis of pharmaceutical products |
| 03/22/2007 | DE102005045152A1 Verwendung von therapeutisch wirksamen Lipiden nebst Verfahren zur Herstellung von Organ-/Gewebe-spezifischen therapeutisch wirksamen Lipiden Use of lipids in addition to therapeutically effective process for the preparation of organ / tissue-specific therapeutically effective lipids |
| 03/22/2007 | CA2820201A1 Identification of tumor-associated antigens for diagnosis and therapy |
| 03/22/2007 | CA2818900A1 Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| 03/22/2007 | CA2622624A1 Topical film-forming monophasic formulations |
| 03/22/2007 | CA2622525A1 Pseudomonas exotoxin a cd4+ t-cell epitopes |
| 03/22/2007 | CA2622468A1 Composition comprising at least one naphthoic acid derivative and at least one compound of polyurethane polymer type or derivatives thereof, preparation processes therefor and uses thereof |
| 03/22/2007 | CA2621492A1 Surfactant systems for delivery of organic compounds |
| 03/22/2007 | CA2621270A1 3-(2-dimethylaminomethyl cyclohexyl) phenol retard formulation |
| 03/22/2007 | CA2620370A1 Extended release pharmaceutical composition of metformin and a process for producing it |
| 03/22/2007 | CA2620362A1 Comb polymers |
| 03/22/2007 | CA2620299A1 Particulate lipid pharmaceutical composition |
| 03/21/2007 | EP1764134A2 Tetrahydroindolone and purine derivatives linked to arylpiperazines |
| 03/21/2007 | EP1764113A1 Antibodies against lung cancer, antigens and methods of use thereof for treating lung cancer |
| 03/21/2007 | EP1764112A2 Linear cyclodextrin copolymers |
| 03/21/2007 | EP1764111A1 Vaginally administered anti-dysrhythmic agents for treating pelvic pain and infertility |
| 03/21/2007 | EP1764103A2 Crystalline amifostine compositions and methods for the preparation and use of same |
| 03/21/2007 | EP1764102A1 Quinolone-containing medicinal composition |
| 03/21/2007 | EP1764100A2 Compositions and methods for reducing vaginal pH |
| 03/21/2007 | EP1764088A1 Thixotropic personal lubricant containing carageenan |
| 03/21/2007 | EP1764085A1 Cosmetic composition comprising argan oil |
| 03/21/2007 | EP1763576A2 Ex-vivo application of solid microparticulate therapeutic agents |
| 03/21/2007 | EP1763513A1 Bi- or tetra-guanidino-biphenyl compounds as small molecule carriers |
| 03/21/2007 | EP1763336A1 Hydrophobic ophthalmic compositions and methods of use |
| 03/21/2007 | EP1763300A1 Use of ether group-containing polymers as solubilizers |
| 03/21/2007 | EP1515710B1 Method of treating rosacea by topical application of a cyclohexane derivative |
| 03/21/2007 | EP1498142B1 Polyfunctional biocompatible hydrogel and method for the production thereof |
| 03/21/2007 | EP1467711B1 Dna dosage forms |
| 03/21/2007 | EP1455782B1 High-concentration stable meloxicam solutions for needle-less injection |
| 03/21/2007 | EP1397127B1 Solid pharmaceutucal formulations comprising modafinil |
| 03/21/2007 | EP1361867B1 Fibrate-statin combinations with reduced fed-fasted effects |
| 03/21/2007 | EP1289529B1 Active substance combination containing a compound with an opioid effect and at least one further compound of formula i |
| 03/21/2007 | EP1242059B1 Novel prodrugs for antimicrobial amidines |
| 03/21/2007 | EP1207872B1 Ibuprofen-containing softgels |
| 03/21/2007 | EP1206485B1 New effectors of dipeptidyl peptidase iv for topical use |
| 03/21/2007 | EP1144013B1 Lactone bearing absorbable polymers |
| 03/21/2007 | EP1133298B1 Compositions comprising cefuroxime axetil |
| 03/21/2007 | EP1115381B1 Proteinic drug delivery system using membrane mimetics |
| 03/21/2007 | EP0954283B1 Use of a non-encapsulated anticancer drug for the preparation of a formulation for treating neoplasms by inhalation |
| 03/21/2007 | EP0817643B1 Compounds and compositions for delivering active agents |
| 03/21/2007 | EP0775496B1 Hydrous composition comprising a cholesterol ester clathrate, a cosmetic containing the same, and processes for the preparation thereof |
| 03/21/2007 | CN2880081Y Medicinal adhering sheets for treating tooth-ache |
| 03/21/2007 | CN1934199A Particle-stabilised emulsions |
| 03/21/2007 | CN1934109A Composition for solid pharmaceutical preparation of solifenacin or salt thereof |
| 03/21/2007 | CN1934093A Pyrimidyl phosphonate antiviral compounds and methods of use |
| 03/21/2007 | CN1933857A Conjugates of hydroxyalkyl starch and a protein |
| 03/21/2007 | CN1933856A Cream-gel containing ivermectin |
| 03/21/2007 | CN1933855A Method of treatment of a metabolic disease using intranasal administration of exendin peptide |
| 03/21/2007 | CN1933853A Drug conjugates |
| 03/21/2007 | CN1933843A Pharmaceutical preparation containing drospirenone for application to the skin |
| 03/21/2007 | CN1933814A S/O type pharmaceutical preparation and process for producing the same |
| 03/21/2007 | CN1933813A Compositions and methods for delivery of biologically active agents |
| 03/21/2007 | CN1933812A Ophthalmic solution comprising sodium carboxymethylcellulose and hydroxypropylmethylcellulose |